Clinical Trial Update: ED90 Determination of Carbetocin for the Prevention of Uterine Atony in Women Undergoing an Elective Cesarean Delivery [Phase 4]

View source ↗

Summary

Clinical trial update reporting ED90 dose determination of carbetocin for prevention of uterine atony in women undergoing elective cesarean delivery (Phase 4).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postpartum Hemorrhage
• Uterine Atony

Drugs mentioned

• Carbetocin (carbetocin)

Snippet

Sponsor: Maisonneuve-Rosemont Hospital | Conditions: Postpartum Hemorrhage, Uterine Atony | Phase 4 | Status: UNKNOWN